What's Happening?
MiniMed, a leader in insulin delivery systems, has announced the expansion of its sensor portfolio in Europe with the CE Mark approval for the MiniMed 780G system, now compatible with the Instinct sensor made by Abbott. This development allows users of the 780G system to
choose between sensors with different wear times, offering more flexibility in diabetes management. The Instinct sensor, noted for being the world's smallest and thinnest integrated continuous glucose monitor (CGM), provides up to 15 days of wear. The MiniMed 780G system is designed to automatically adjust insulin delivery based on real-time glucose readings, aiming to reduce the burden of diabetes management.
Why It's Important?
The CE Mark approval for the MiniMed 780G system with the Instinct sensor is a significant advancement in diabetes care, providing patients with more options for managing their condition. This flexibility can lead to improved adherence to treatment plans and better overall health outcomes for individuals with diabetes. The integration of advanced sensors into insulin delivery systems represents a growing trend towards personalized and automated healthcare solutions. This development could influence the broader medical device market by setting new standards for sensor technology and diabetes management.
What's Next?
MiniMed plans to launch the 780G system with the Instinct sensor in select European countries by summer 2026. The company will also present the system at the upcoming International Conference on Advanced Technologies and Treatments for Diabetes in Barcelona. In the U.S., clinical trials are underway to expand the use of the 780G system to younger age groups. As these developments unfold, MiniMed may continue to innovate and expand its product offerings, potentially influencing regulatory standards and market dynamics in the diabetes care industry.
